JP Morgan Chase
XBIO icon

JP Morgan Chase’s Xenetic Biosciences XBIO Stock Holding History

JP Morgan Chase’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$876 – 7765
2024
Q3 		$876 Buy
+200
New +$787 ﹤0.01% 6740

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LGF
LGT Group Foundation Vaduz, Liechtenstein $8.19B AUM 27.7% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIP
Alexis Investment Partners Montgomery, Texas $171M AUM 32.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's XBIO Position: Q4 2024 in Review

JP Morgan Chase sold out of Xenetic Biosciences (XBIO) in Q4 2024, closing a stake of 200 shares — an estimated $876 sold.

JP Morgan Chase first reported a position in XBIO in Q3 2024 and held it in 1 quarter. The position peaked at $876 in Q3 2024. 13 funds tracked by Wall St. Rank hold XBIO as of Q4 2024.

  • JP Morgan Chase reported no remaining Xenetic Biosciences position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 200 Xenetic Biosciences shares in Q4 2024, an estimated $876.
  • JP Morgan Chase first reported a position in Xenetic Biosciences in Q3 2024 and held it in 1 quarter.
  • JP Morgan Chase's Xenetic Biosciences position peaked at $876 in Q3 2024.
  • 13 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.